Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2026-02-02 00:00:00 ET · period of report 2026-01-30 · accession 0001652410-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-02 | 2026-02-02 | XERS | Hecht Beth | See Remarks | S - Sale | $7.45 | -16.7K | 1.24M | -1% | -$124.2K |
| DM | 2026-02-02 | 2026-01-31 | XERS | Hecht Beth | See Remarks | F - Tax | $7.36 | -169.6K | 1.33M | -11% | -$1.25M |
| D | 2026-02-02 | 2026-01-30 | XERS | Hecht Beth | See Remarks | A - Grant | $0.00 | +121.3K | 1.43M | +9% | $0 |
| D | 2026-02-02 | 2026-01-30 | XERS | Hecht Beth | See Remarks | A - Grant | $0.00 | +162.2K | 162.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-02 | S | D | 16,667 | $7.45 | 1,243,174 | D | — | — | (F4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.590, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Stock | 2026-01-31 | F | D | 46,914 | $7.36 | 1,284,107 | D | — | — | (F2) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. |
| 3 | Common | Common Stock | 2026-01-31 | F | D | 24,266 | $7.36 | 1,259,841 | D | — | — | (F2) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. |
| 4 | Common | Common Stock | 2026-01-30 | A | A | 121,293 | $0.00 | 1,429,396 | D | — | — | (F1) These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date. |
| 5 | Common | Common Stock | 2026-01-31 | F | D | 98,375 | $7.36 | 1,331,021 | D | — | — | (F2) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-01-30 | A | A | 162,162 | $0.00 | 162,162 | D | $7.36 · — to 2036-01-30 | 162,162 Common Stock | (F5) These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date. |